Boston Scientific (STU:BSX) Cyclically Adjusted PS Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BSX Boston Scientific Corp STU:BSX
74 GF Score
Price €42.41
GF Value €90.94
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Boston Scientific  (STU:BSX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Boston Scientific Cyclically Adjusted PS Ratio Related Terms


Boston Scientific Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Boston Scientific's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Cyclically Adjusted PS Ratio Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.89 5.86 6.85 9.83 9.62

Boston Scientific Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.22 9.98 9.62 6.12 0.00

STU:BSX vs EW, DXCM, GEHC: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Boston Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Cyclically Adjusted PS Ratio falls into.


STU:BSX
74GF Score
Boston Scientific Corp STU:BSX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Boston Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Boston Scientific's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.203/333.9520*333.9520
=3.203

Current CPI (Jun. 2026) = 333.9520.

Boston Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.359 241.428 1.880
201612 1.501 241.432 2.076
201703 1.453 243.801 1.990
201706 1.444 244.955 1.969
201709 1.337 246.819 1.809
201712 1.458 246.524 1.975
201803 1.381 249.554 1.848
201806 1.524 251.989 2.020
201809 1.461 252.439 1.933
201812 1.601 251.233 2.128
201903 1.567 254.202 2.059
201906 1.653 256.143 2.155
201909 1.741 256.759 2.264
201912 1.849 256.974 2.403
202003 1.628 258.115 2.106
202006 1.261 257.797 1.634
202009 1.578 260.280 2.025
202012 1.560 260.474 2.000
202103 1.616 264.877 2.037
202106 1.783 271.696 2.192
202109 1.736 274.310 2.113
202112 1.927 278.802 2.308
202203 1.910 287.504 2.219
202206 2.134 296.311 2.405
202209 2.223 296.808 2.501
202212 2.121 296.797 2.387
202303 2.189 301.836 2.422
202306 2.281 305.109 2.497
202309 2.241 307.789 2.431
202312 2.313 306.746 2.518
202403 2.394 312.332 2.560
202406 2.579 314.175 2.741
202409 2.550 315.301 2.701
202412 2.923 315.605 3.093
202503 2.889 319.799 3.017
202506 2.938 322.561 3.042
202509 2.886 324.800 2.967
202512 3.018 324.054 3.110
202603 3.010 330.213 3.044
202606 3.203 333.952 3.203

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Boston Scientific (STU:BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of €42.41 is trading 53.4% below its estimated GF Value™ of €90.94. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for STU:BSX:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €90.94 vs. price of €42.41 (53.4% below fair value)
  • GF Score™: 74/100 with 1 warning sign

No single metric tells the full story. See the STU:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
74GF Score

Get the complete analysis for STU:BSX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.41
Price
€90.94
GF Value